Natasa Bogavac Stanojevic, PhD

Dr sc. Nataša Bogavac-Stanojević

Position: Full Professor
Organisational Unit: Department of Medical Biochemistry
Room: А206
Phone: +381 11 3951-269


Nataša Bogavac-Stanojević acquired her PhD in 2007 at the Department of Medical Biochemistry-Faculty of Pharmacy and completed post-doctoral training at the Faculty of Pharmacy, the University of Ljubljana in 2011 and 2012. In 2006, she completed specialist academic studies of pharmacoeconomics and pharmaceutical legislation. Nataša Bogavac-Stanojević has been employed at the Department of Medical Biochemistry-Faculty of Pharmacy since 1995. She was elected assistant professor in Medical Biochemistry in 2008, an associate professor in 2013, and became a full professor in 2018.

Nataša Bogavac-Stanojević received a scholarship from the Ministry of Science and Environmental Protection for her post-doctoral training and a scholarship from the Basileus III project in 2012 for the same study training. She has won two international awards (ISCB Conference Award for Scientists) for the best scientific work in biostatistics. Furthermore, she took part in the CEPUS III project for short term mobility for teaching assignments at the Faculty of Pharmacy and Biochemistry, University of Zagreb (2012 and 2013) and at the University of Pecs, Faculty of Medicine (2016). In 2019 she obtained at the Lithuanian University of Health Sciences mobility for teaching assignments in the field of quality of life.

Nataša Bogavac-Stanojević is the head of the Department of Medical Biochemistry. From 2012 to 2018, she was the Vice Dean for Finance at the Faculty of Pharmacy. She is engaged in the Commission for Standards and Related Documents at the Institute for Standardization of Serbia and in several working groups of the Ministry of Health of the Republic of Serbia.

Her main research interest is the investigation of risk factors for the development of cardiovascular diseases and the economic evaluation of new biomarkers. She has been engaged in the Innovation Fund of the Republic of Serbia projects (innovative vouchers and proof of concept). She is involved in several international projects within the COST initiative. Nataša Bogavac-Stanojević is a member of the EFLM Task and Finish Group for Laboratory Diagnosis of Chronic Kidney Disease (TFG-CKD) and a corresponding member of the Laboratory Guidelines Working Group (EFLM). More than 88 SCI scientific papers listed on her name were published.

  • Levic M, Bogavac-Stanojevic N, Krajnovic D. The Instruments Used to Assess Health Literacy and Pharmacotherapy Literacy of Diabetes Mellitus Type 2 Patients: A Scoping Review. Frontiers in Public Health. 2021. 10.3389/fpubh.2021.747807
  • Dejanović VV, Stevuljević JK, Vukašinović A, Miljković M, Kafedzic S, Zdravković M, Ilić I, Hinić S, Cerović M, Stefanović M, Spasojević-Kalimanovska V, Memon L, Nešković AN, Bogavac-Stanojević N. Oxidative stress and inflammatory markers PTX3, CypA, and HB-EGF: how are they linked in patients with STEMI? Angiology. 2020;71:713-720.
  • Bogavac-Stanojevic N, Kotur-Stevuljevic J, Cerne D, Zupan J, Marc J, Vujic Z, Crevar-Sakac M, Sopic M, Munjas J, Radenkovic M, Jelic-Ivanovic Z. The role of artichoke leaf tincture (Cynara scolymus) in the suppression of DNA damage and atherosclerosis in rats fed an atherogenic diet. Pharm Biol 2018; 56(1): 138-144.
  • Stevanovic M, Vekic J, Bogavac-Stanojevic N, Janac J, Stjepanovic Z, Zeljkovic D, Trifunovic B, Spasojevic-Kalimanovska V, Zeljkovic A. Significance of LDL and HDL subclasses characterization in the assessment of risk for colorectal cancer development. Biochem Med 2018; 28:030703.
  • Petrovic S,  Bogavac-Stanojevic N,  Lakic D,  Peco-Antic A,  Vulicevic I,  Ivanisevic I, Kotur-Stevuljevic J,  Jelic-Ivanovic Z.  Cost-effectiveness analysis of acute kidney injury biomarkers in pediatric cardiac surgery. Biochem Med 2015; 25 (2): 262-271.
  • Petrovic S, Bogavac-Stanojevic N, Kotur-Stevuljevic J, Peco-Antic A, Ivanisevic I, Ivanisevic J, Paripovic D, Jelic-Ivanovic Z. Oxidative status parameters in children with urinary tract infection. Biochem Med 2014;24:266-72.
  • Spasojevic-Kalimanovska V,  Bogavac-Stanojevic N,  Kalimanovska-Ostric, Memon L,  Spasic S, Kotur-Stevuljevic J,  Jelic-Ivanovic Z.  Factor analysis of risk variables associated with iron status in patients with coronary artery disease. Clin Biochem 2014;47(7-8):564-9.
  • Petrovic S, Bogavac-Stanojevic N,  Peco-Antic A, Ivanisevic I, Kotur-Stevuljevic J, Paripovic D, Sopic M, Jelic-Ivanovic Z. Clinical application neutrophil gelatinase-associated lipocalin and kidney injury molecule-1 as indicators of inflammation persistence and acute kidney injury in children with urinary tract infection. Biomed Res Int 2013, Article ID 947157, 9 pages
  • Lakic D, Bogavac-Stanojevic N, Jelic-Ivanovic Z, Kotur-Stevuljevic J, Spasic S, Kos M. A Multimarker Approach for the Prediction of Coronary Artery Disease: Cost Effectiveness Analysis. Value in health 2010; 13: 770-777.
  • Bogavac-Stanojević N, Đurović S, Jelić-Ivanović Z, Spasojević-Kalimanovska V, Kalimanovska-Oštrić D. Circulating transforming growth factor-b1, lipoprotein (a) and cellular adhesion molecules in angiographicaly assessed coronary artery disease. Clin Chem Lab Med 2003; 41(7): 893-898